<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833350</url>
  </required_header>
  <id_info>
    <org_study_id>GA29350</org_study_id>
    <secondary_id>2016-000335-40</secondary_id>
    <nct_id>NCT02833350</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)</brief_title>
  <official_title>A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response or Intolerance to Previous TNF Therapy (Cohort 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active
      comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and
      safety of GDC-0853 in participants with moderate to severe active RA and an inadequate
      response to previous methotrexate (MTX) therapy (Cohort 1) or MTX and tumor necrosis factor
      (TNF) therapy who may have also had exposure to no more than one non-TNF inhibitor biologic
      (Cohort 2).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 9, 2016</start_date>
  <completion_date type="Anticipated">June 26, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 26, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 1)</measure>
    <time_frame>Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Day 1 up to 8 weeks after last dose (up to Week 20)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Adalimumab (Cohort 1)</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 2)</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing High Disease Activity to Clinical Remission Using the Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing High Disease Activity to Clinical Remission Using the Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing High Disease Activity to Clinical Remission Using the Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing High Disease Activity to Clinical Remission Using the Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR50 Response</measure>
    <time_frame>Days 7, 14, 28, and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Response as Assessed by Tender/Painful Joint Count (68 Joint Count)</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Response as Assessed by Swollen Joint Count (66 Joint Count)</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Response as Assessed by Patient Assessment Score of Arthritis Pain</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Response as Assessed by Patient Global Assessment Score of Arthritis Pain</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Response as Assessed by Physician's Global Assessment Score of Arthritis</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Response as Assessed by C-Reactive Protein (CRP) Levels</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Response as Assessed by Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the Boolean-based Remission Criteria</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the Simplified Disease Activity Index (SDAI)-based Remission Criteria</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the Clinical Disease Activity Index (CDAI)-based Remission Criteria</measure>
    <time_frame>Days 7, 14, 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Score</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score</measure>
    <time_frame>Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve From Time 0 to Time t of GDC-0853 at Steady State (AUC0-t,ss)</measure>
    <time_frame>Pre-dose (0 hours) on Days 28, 56, and 84 and up to 10 hours post-dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration of GDC-0853 at Steady State (Cmax,ss)</measure>
    <time_frame>Pre-dose (0 hours) on Days 28, 56, and 84 and up to 10 hours post-dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration of GDC-0853 at Steady State (Tmax,ss)</measure>
    <time_frame>Pre-dose (0 hours) on Days 28, 56, and 84 and up to 10 hours post-dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Plasma Concentration of GDC-0853 at Steady State (Ctrough,ss)</measure>
    <time_frame>Pre-dose (0 hours) on Days 28, 56, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life of GDC-0853 at Steady State (t1/2,ss)</measure>
    <time_frame>Pre-dose (0 hours) on Days 28, 56, and 84 and up to 10 hours post-dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance of GDC-0853 at Steady State (CL/F,ss)</measure>
    <time_frame>Pre-dose (0 hours) on Days 28, 56, and 84 and up to 10 hours post-dose on Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SDAI at Days 7, 14, 28, 56 and 84</measure>
    <time_frame>Baseline, Days 7, 14, 28, 56 and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CDAI at Days 7, 14, 28, 56 and 84</measure>
    <time_frame>Baseline, Days 7, 14, 28, 56 and 84</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">578</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Cohort 1: GDC-0853 High Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants of Cohort 1 will receive GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants of Cohort 1 will receive GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants of Cohort 1 will receive GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: GDC-0853 Placebo + Adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: GDC-0853 Placebo + Adalimumab Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: GDC-0853 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants of Cohort 2 will receive GDC-0853 high dose, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: GDC-0853 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants of Cohort 2 will receive placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0853</intervention_name>
    <description>Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.</description>
    <arm_group_label>Cohort 1: GDC-0853 High Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 2: GDC-0853 High Dose</arm_group_label>
    <other_name>RO7010939</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.</description>
    <arm_group_label>Cohort 1: GDC-0853 Placebo + Adalimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.</description>
    <arm_group_label>Cohort 1: GDC-0853 High Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Placebo + Adalimumab</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Placebo + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 2: GDC-0853 High Dose</arm_group_label>
    <arm_group_label>Cohort 2: GDC-0853 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).</description>
    <arm_group_label>Cohort 1: GDC-0853 High Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Placebo + Adalimumab</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Placebo + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 2: GDC-0853 High Dose</arm_group_label>
    <arm_group_label>Cohort 2: GDC-0853 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.</description>
    <arm_group_label>Cohort 1: GDC-0853 High Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Placebo + Adalimumab</arm_group_label>
    <arm_group_label>Cohort 1: GDC-0853 Placebo + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Cohort 2: GDC-0853 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of adult-onset RA as defined by the 2010 American College of
             Rheumatology/European League Against Rheumatism Classification Criteria for RA

          -  RA disease activity by joint counts and laboratory markers of inflammation: greater
             than or equal to (&gt;=) 6 tender/painful joints on motion (68 joint count) and &gt;= 6
             swollen joints (66 joint count) at both screening and Day 1 (randomization)

          -  For MTX-inadequate response (IR) participants: must have had an inadequate response to
             MTX

          -  For TNF-IR participants: must have had an inadequate response or intolerance to
             previous treatment with at least 1 and no more than 2 biologic TNF-alpha inhibitors
             and may have also been exposed to no more than one biologic non-TNF-alpha inhibitor

          -  High sensitivity C-reactive protein of &gt;= 0.400 milligrams per deciliter (mg/dL) for
             Cohort 1 and &gt;= 0.650 mg/dL for Cohort 2 at screening

        Exclusion Criteria:

          -  History of or current inflammatory joint disease other than RA or other systemic
             autoimmune disorder

          -  For MTX-IR participants: History of treatment with any TNF inhibitor, including
             biosimilar equivalents and history of treatment with biologic non-TNF-alpha inhibitor
             for RA

          -  For all participants: Previous treatment with cell-depleting therapy including B
             cell-depleting therapy (e.g., anti-cluster of differentiation 20-directed therapy such
             as rituximab), tofacitinib, or other Janus kinase inhibitor(s), or alkylating agents

          -  Current treatment with medications that are well known to prolong the QT interval at
             doses that have a clinically meaningful effect on QT

          -  History of non-gallstone-related pancreatitis or chronic pancreatitis

          -  Evidence of serious uncontrolled concomitant cardiac, neurologic, pulmonary, renal,
             hepatic, endocrine, metabolic, or gastrointestinal disease

          -  Evidence of chronic and/or active hepatitis B or C

          -  Women who are pregnant, nursing (breast feeding), or intending to become pregnant
             during the study or within 60 days after completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group; Llc, Central</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Associates, P.C.</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates, LLC</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jude Heritage Medical Grp</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5151</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RASF-Clinical Research Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZASA Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InVentiv Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McIlwain Medical Group</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Arthritis Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medication Management</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Inst.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management - VO</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinical Research, LLC</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danville Orthopedic Clinic, Inc.; Research Department</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas-Mar del Plata</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Organizacion Medica de Investigacion</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APRILLUS</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1194AAO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto centenario</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1204AAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Enfermedades Reumaticas CIER</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1055AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Expertia S.A- Mautalen Salud e Investigación</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1128AAE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR - Buenos Aires - AR; AxisMed SRL</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1430CKE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ILAIM-CEOM Inst. Latinoamericano de Inv. Medicas</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000BNB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de La Plata</name>
      <address>
        <city>La Plata</city>
        <zip>1725</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Medicas Mar Del Plata</name>
      <address>
        <city>Mar del Plata</city>
        <zip>B7600DHK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clínicas Quilmes</name>
      <address>
        <city>Quilmes</city>
        <zip>1878</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica</name>
      <address>
        <city>San Juan</city>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado de Reumatologia; Reumathology</name>
      <address>
        <city>San Miguel</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIP - Centro Internacional de Pesquisa; Pesquisa Clinica</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Mineiro de Pesquisa - CMIP</name>
      <address>
        <city>Juiz de Fora</city>
        <state>MG</state>
        <zip>36036-330</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edumed - Educação e Saúde SA</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80440-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos em Terapias Inovadoras - CETI</name>
      <address>
        <city>Curtiba</city>
        <state>PR</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR - Synarc Centro de Pesquisa Clinica - RJ</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Vicente de Paulo</name>
      <address>
        <city>Passo Fundo</city>
        <state>RS</state>
        <zip>99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMK Serviços Médicos S/S</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90480-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAEP - Centro Avancado de Estudos e Pesquisas Ltda.</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13087-567</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC - FMABC</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clínica e Medicina Avançada Ltda</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05437-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Faculdade Regional de Medicina de São José do Rio Preto</name>
      <address>
        <city>São José do Rio Preto</city>
        <state>SP</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPCLIN - Centro de Pesquisas Clínicas Ltda.; Pesquisa Clinica</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01244-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT - Dobrich, AD</name>
      <address>
        <city>Dobrich</city>
        <zip>9300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Eurohospital&quot; - Plovdiv, OOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Kaspela; EOOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT - Ruse, AD</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinski Zentrar-1-Sevlievo EOOD</name>
      <address>
        <city>Sevlievo</city>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Hadzhi Dimitar&quot;, OOD</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Excelsior OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NMTH &quot;Tsar Boris III&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Lyulin&quot;, EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1336</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC &quot;Alexandrovska&quot;, EOOD; Clinic of Neurology</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;SofiaMed&quot;, OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1750</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC &quot;Synexus - Sofia&quot;, EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Dr. St. Kirkovich, AD</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>'New Medical Center' , EOOD</name>
      <address>
        <city>Vratsa</city>
        <zip>3000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Reumatologia y Ortopedia</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riesgo de Fractura S.A.</name>
      <address>
        <city>Bogota D.C.</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Reumatologia y Especialdades Medicas SAS. CIREEM</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto de Reumatología Fernando Chalem</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Artritis Temprana S.A.</name>
      <address>
        <city>Cali</city>
        <zip>00000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin-Antioquia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital; Department of Internal Medicine (Rheumatology)</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación de Tratamientos Innovadores de Sinaloa (CITI)</name>
      <address>
        <city>Culiacán Rosales</city>
        <state>Sinaloa</state>
        <zip>80000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Reumatologia</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Particular del Dr. Miguel Cortes Hernandez</name>
      <address>
        <city>Cuernavaca</city>
        <zip>62290</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Medico en Fundacion el Hospitalito de morelos A.C.</name>
      <address>
        <city>Cuernavaca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Enfermedades Reumaticas y Osteoporosis</name>
      <address>
        <city>Mexicali</city>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clínica GRAMEL S.C</name>
      <address>
        <city>Mexico</city>
        <zip>03720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policilinica Medica de Queretaro; Rheumatology</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Tlalnepantla</city>
        <zip>54055</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Enfermedades Reumaticas y Cronicodegenerativas</name>
      <address>
        <city>Torreon</city>
        <zip>27000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ OSTEO-MEDIC S.C. Artur Racewicz, Jerzy Supronik</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki; nr 2 im. Dr J. Biziela</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medica Pro Familia Spolka Akcyjna Oddzial w Katowicach</name>
      <address>
        <city>Katowice</city>
        <zip>40-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Plejady</name>
      <address>
        <city>Krakow</city>
        <zip>30-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR - Lodz - PL</name>
      <address>
        <city>Lodz</city>
        <zip>90-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETYKA Osrodek Badan Kliniczynch</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-117</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ai Centrum Medyczne Sp. Z O.O Sp.K.</name>
      <address>
        <city>Poznan</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Staszow</name>
      <address>
        <city>Staszow</city>
        <zip>28-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna</name>
      <address>
        <city>Warszawa</city>
        <zip>00-660</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne AMED</name>
      <address>
        <city>Warszawa</city>
        <zip>03-291</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny we Wrocławiu</name>
      <address>
        <city>Wrocław</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Zamosc</name>
      <address>
        <city>Zamosc</city>
        <zip>22400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TSBIH &quot;Krasnoyarsk Interdistrict Clinical Hospital of Emergency Medical Care n.a. N.S. Karpovich</name>
      <address>
        <city>Krasnoyarsk</city>
        <state>Krasnojarsk</state>
        <zip>660062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaja Oblast</state>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBIH of Moscow &quot;City Clinical Hospital # 1 n. a. N. I. Pirogov&quot;</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaja Oblast</state>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE &quot; First Moscow State Medical University n.a. I.M. Sechenov&quot; of the MoH of the RF</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaja Oblast</state>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technologii zdorovia LLC</name>
      <address>
        <city>Sankt-peterburg</city>
        <state>Sankt Petersburg</state>
        <zip>191144</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanavita LLC</name>
      <address>
        <city>Sankt-peterburg</city>
        <state>Sankt Petersburg</state>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Medical Sanitary Unit</name>
      <address>
        <city>Sankt-peterburg</city>
        <state>Sankt Petersburg</state>
        <zip>196066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Family Medicine LC</name>
      <address>
        <city>Yekaterinburg</city>
        <state>Sankt Petersburg</state>
        <zip>620043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of Yaroslavl Region Clinical Hospital #3</name>
      <address>
        <city>Yaroslavl</city>
        <state>Volgograd</state>
        <zip>150051</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMMIH &quot;Chelyabinsk Regional Clinical Hospital&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <state>Voronez</state>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAHI of Kem. &quot;Regional Clinical Hospital for War Veterans&quot;</name>
      <address>
        <city>Kemerovo</city>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OOO Family Polyclinic</name>
      <address>
        <city>Korolev, Moscow Region</city>
        <zip>141060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practical Medicine</name>
      <address>
        <city>Moscow</city>
        <zip>115404</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Centre of Medical Common Practice&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultramed</name>
      <address>
        <city>Omsk</city>
        <zip>644024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE &quot;Saratov State Medical University n.a. V. I. Razumovskiy&quot; of the MoH of the RF</name>
      <address>
        <city>Saratov</city>
        <zip>410026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE &quot;Smolensk State Medical University&quot; of the MoH of the RF</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital 25; Rheumatology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siberian State Medical University</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI Ulyanovsk Reg Clinical Hospital</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Territorial Clinical Hospital #2</name>
      <address>
        <city>Vladivostok</city>
        <zip>690035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI Yaroslavl Regional Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11040</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Treatment and Rehabilitation &quot;Niska Banja&quot;</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Special hospital for rheumatic diseases Novi Sad</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Sabac; Department of Urology and Hemodialysis</name>
      <address>
        <city>Sabac</city>
        <zip>15000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI of TRC</name>
      <address>
        <city>Ternopil</city>
        <state>Kherson Governorate</state>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional CH Dep of Rheumatology SHEI Ivano-Frankivsk NMU</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>KIEV Governorate</state>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Medical Clinic Blagomed LLC.</name>
      <address>
        <city>Kyiv</city>
        <state>KIEV Governorate</state>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center OK!Clinic+</name>
      <address>
        <city>Kyiv</city>
        <state>KIEV Governorate</state>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI NSС M.D. Strazhesko Institute of Cardiology of NAMSU</name>
      <address>
        <city>Kyiv</city>
        <state>KIEV Governorate</state>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Modern Rheumatology Revmotsentr LLC</name>
      <address>
        <city>Kyiv</city>
        <state>KIEV Governorate</state>
        <zip>04071</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Clinical Hospital Dept of Rehmuaatology D. Halytskyi Lviv NMU</name>
      <address>
        <city>Lviv</city>
        <state>KIEV Governorate</state>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH of State Border Service of Ukraine (Military Base 2522); Dept of Therapy, D.Halytskyi Lviv NMU</name>
      <address>
        <city>Lviv</city>
        <state>KIEV Governorate</state>
        <zip>79014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.Novak Transcarpathian Regional Clinical Hospital</name>
      <address>
        <city>Uzhgorod</city>
        <state>KIEV Governorate</state>
        <zip>88018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Railway Transp DCH of HealthCenter Branch of PJSC Ukr Railway Dept of Rheumatology</name>
      <address>
        <city>Dnipro</city>
        <state>Tavria Okruha</state>
        <zip>49008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv MA of PGE of MOHU Ch of Cardiology and Functional Diagnostics</name>
      <address>
        <city>Kharkiv</city>
        <zip>61176</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNI Consultative and Diagnostic Center of Desnianskyi District of Kyiv</name>
      <address>
        <city>Kyiv</city>
        <zip>02232</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MI of Helathcare Kyiv RCH P.L. Shupy NMA of PGE</name>
      <address>
        <city>Kyiv</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gerontology Institute of the Ukrainian AMS</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oleksandrivska Clinical Hospital</name>
      <address>
        <city>Kyiv</city>
        <zip>1023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volyn Regional Center of Cardiovascular Pathology and Thrombolysis</name>
      <address>
        <city>Lutsk</city>
        <zip>43024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #1</name>
      <address>
        <city>Mykolaiv</city>
        <zip>54003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.V. Sklifosovsky Poltava RCH Dept of Rheumatology HSEIU UMSA</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Small Enterprise Medical Center Pulse</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.I. Pyrogov VRCH Dept of Gastroenterology M.I. Pyrogov VNMU</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #9 Dept of Gastrosurgery SI Zaporizhzhia MA of PGE of MoHU</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69096</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI City Hospital #7</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69118</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI Zaporizhzhia Regional Clinical Hospital of ZRC</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Chile</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

